Atherosclerotic cardiovascular disease (ASCVD) continues to be a major global killer, and elevated LDL cholesterol (LDL-C) remains a key, modifiable driver. PCSK9 has emerged as a central therapeutic target because it controls hepatic LDL receptor recycling and thereby shapes circulating LDL-C levels. While PCSK9 monoclonal antibodies and siRNA can markedly lower LDL-C, their cost and repeated dosing motivate the search for longer-lasting, more accessible interventions.
In a new preclinical study in Life Metabolism, researchers led by Prof. Ruiping Xiao at Peking University explored a structure-guided peptide vaccine aimed at PCSK9. The central question was whether a carefully selected PCSK9 B-cell epitope—paired with a heterologous T-helper epitope—could elicit durable anti-PCSK9 antibodies and translate into lipid and atherosclerosis benefits in vivo.
To design the immunogen, the team analyzed PCSK9–antibody complex structures from the Protein Data Bank and used AlphaFold3-guided modeling to pinpoint conserved, antibody-exposed regions on PCSK9. Three peptide vaccine constructs were evaluated, and one formulation, PVC3, combined with CpG plus alum, produced the strongest PCSK9-specific antibody response.
In mice, PVC3 induced long-lasting immunity, with antibody titers detectable for up to 24 weeks. Similar immunogenicity was observed beyond rodents: the vaccine also triggered antibody responses in guinea pigs and rhesus macaques. Importantly for early development, safety screening in mice did not reveal overt systemic toxicity or major organ histopathology changes.
Mechanistically, the study reports no detectable T-cell response when the PCSK9 B-cell epitope was tested alone, supporting a favorable preclinical safety profile. The investigators then assessed functional effects using two hypercholesterolemic mouse models.
In an AAV-hPCSK9D374Y model, vaccination curtailed LDL-C and total cholesterol increases after AAV challenge and reduced hepatic lipid accumulation. In ApoE-deficient mice, which spontaneously develop atherosclerotic lesions, PVC3 reduced LDL-C elevation by 29% at week 4 and by 20% at week 14 versus controls. It also decreased aortic lesion area and lowered the necrotic-core fraction within aortic-root plaques.
Non-human primate results were more nuanced. In healthy rhesus macaques, PVC3 generated robust anti-PCSK9 antibodies without obvious liver or kidney or autoimmune safety signals in the assays performed. However, it did not significantly change LDL-C, total cholesterol, HDL-C, or triglycerides compared with controls, suggesting efficacy may depend on disease state.
Overall, the work presents a rational proof-of-concept for active immunization against PCSK9. The authors emphasize that translation will require further optimization and testing in dyslipidemic larger-animal models, alongside mechanistic assays probing LDL receptor protection, circulating free PCSK9, and PCSK9-neutralizing activity. As with all preclinical studies, these findings do not establish human efficacy or safety, but they outline a potential long-term vaccine strategy for ASCVD risk management.
Subject of Research: Not applicable
Article Title: Structure-guided design of a PCSK9 epitope vaccine with efficacy against hyperlipidemia and atherosclerosis
News Publication Date: 26-May-2026
Web References: http://dx.doi.org/10.1093/lifemeta/loag013
References: 10.1093/lifemeta/loag013
Image Credits: HIGHER EDUCATION PRESS
Keywords: PCSK9, peptide vaccine, epitope design, CpG plus alum, LDL-C, atherosclerosis
Tags: atherosclerotic cardiovascular disease preventionB-cell epitope mapping using AlphaFold3immunogenicity testing in preclinical modelsLDL cholesterol reduction strategieslong-lasting antibody responses in mice and primatesPCSK9 monoclonal antibodies and siRNA therapiespeptide vaccine design for lipid regulationpotential for durable lipid-lowering immunotherapiesstructure-guided PCSK9 vaccinetargeting PCSK9 to prevent atherosvaccine formulation with CpG and alum adjuvants
